间变性淋巴瘤激酶抑制剂治疗肿瘤研究回顾  

Research Progress of Anaplastic Lymphoma Kinase(ALK) Inhibitors in Treating Cancer

作　　者：赵英玲 罗玲[1] 叶春桃[1] 饶晨[1] 冯碧珊 肖小灵 黄望香[1] ZHAO Yingling;LUO Ling;YE Chuntao;RAO Chen;FENG Bishan;XIAO Xiaoling;HUANG Wangxiang(Longgang Central Hospital of Shenzhen City,Guangdong Shenzhen 518100,China)

机构地区：[1]广东省深圳市龙岗中心医院血液科,广东深圳518100

出　　处：《中医药临床杂志》2020年第9期1610-1614,共5页Clinical Journal of Traditional Chinese Medicine

基　　金：深圳龙岗区经济与科技发展专项资金资助(项目编号:20170405181637744)。

摘　　要：间变性淋巴瘤激酶(Anaplastic lymphoma kinase,ALK)作为一种与肿瘤密切相关的酪氨酸激酶,可被易位或突变激活,出现异常表达如基因突变、重排及扩增等,激活体内的细胞信号传导通路,调控肿瘤的生长、分化、迁移。ALK小分子抑制剂类抗肿瘤药物虽然已经被批准正式应用于临床肿瘤的治疗,然而新的耐药突变问题也不断出现,导致肿瘤反复。通过查阅文献,回顾近年来对ALK抑制剂的研究、中医药认识以及临床治疗进展。Anaplastic lymphoma kinase (ALK),as a tyrosine kinase closely related to tumors,can be activated by translocations or mutations.Abnormal expressions such as gene mutations,rearrangements and amplifications can activate in vivo The cell signal transduction pathway,which regulates tumor growth,differentiation and migration.Although ALK small molecule inhibitor anti-tumor drugs have been approved and formally used in the treatment of clinical tumors,new drug-resistant mutations continue to appear,causing tumor recurrence.By consulting the literature,review the research on ALK inhibitors,the understanding of traditional Chinese medicine and the progress of clinical treatment in recent years.

关 键 词：间变性淋巴瘤激酶抑制剂 肿瘤 中医药 

分 类 号：R273[医药卫生—中西医结合]